

What's Happening to the Mentally Ill

Colton, CW and Manderscheid, RW (2006). "Congruencies in Increased Mortality Rates, Years of Potential Life Lost, and Causes of Death Among Public Mental Health Clients in Eight States," *Preventing Chronic Disease: Public Health Research, Practice, and Policy* 3 (2):1-14.

Lutterman T, Ganju V, Schacht L, Shaw R, Monihan K et al (2003). Sixteen State Study on Mental Health Performance Measures. DHHS Publication No. (SMA) 03-3835. Rockville, MD: Center for Mental Health Services, Substance Abuse and Mental Health Services Administration.

Parks J, Svendsen D, Singer P, and Foti ME, Ed. (October 2006). "Morbidity and Mortality in People with Serious Mental Illness." Thirteenth in a Series of Technical Reports. National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council.

Freeman E, and Yoe JT. *The Poor Health Status of Consumers of Mental Healthcare: Behavioral Disorders and Chronic Disease*, Presentation to NASMHPD Medical Directors Work Group, May 2006. Accessed on 6/11/10 at:
http://www.nri-inc.org/conferences/Presentations/2008/06a_FreemanIntro.pdf

Yoe JT and Freeman E. (June 19, 2009). The Interdependence of Mental Health and Physical Health. Presented at the SAMHSA National Grantee Conference – Washington, DC.

America's Drug Problem

Express Scripts (April 2010). *2009 Drug Trend Report: Solving for America's \$163 Billion in Pharmacy-Related Waste*. Accessed on 6/12/10 at:
<http://www.express-scripts.com/research/studies/drugtrendreport/>

Hoyert DL and Xu, J. Deaths: Preliminary Data for 2011. National Vital Statistics Reports, Vol. 61 No. 6. Atlanta, GA: U.S. Department of Health and Human Services – Centers for Disease Control and Prevention, 2012.

IMS – *Top Therapeutic Classes by U.S. Sales – 2005 through 2009*. Accessed 6/6/10 at:
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Top%20Therapy%20Classes%20by%20U.S.Sales.pdf

IMS – *Top 15 Global Therapeutic Classes, 2009*. Accessed 6/6/10 at:
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Top%2015%20Global%20Therapeutic%20Classes_2009.pdf

IMS – *Top Therapeutic Classes by U.S. Dispensed Prescriptions – 2005 through 2009*. Accessed 6/6/10 at:
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Top%2015%20Products%20by%20U%20S%20RXs.pdf

National Academy of Sciences Institute of Medicine (2000). *To Err is Human: Building A Safer Health System*. Accessed on May 27, 2009 at:
<http://www.iom.edu/Object.File/Master/4/117/ToErr-8pager.pdf>

Population Reference Bureau (2010). *2009 World Population Data Sheet*. Available at
http://www.prb.org/pdf09/09wpds_eng.pdf

Starfield B (2000). “Is U.S. Health Care Really the Best in the World,” *JAMA* 284 (4): 483-485.

U.S. Census Bureau, Population Division (December 2009). *Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2000 to July 1, 2009*.

Antipsychotics and Heart Disease

Curkendall SM, Mo J, Glasser DB, Rose Tang M, Jones JK (2004). Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. *Journal of Clinical Psychiatry* 65 (5):715-720.

DeHert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, et al (2011). Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. *World Psychiatry* 10:52-77.

Enger C, Weatherby L, Reynolds RF, Glasser DB, and Walker AM (2004). Serious cardiovascular events and mortality among patients with schizophrenia. *Journal of Nervous and Mental Disease* 192 (1):19-27.

Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S et al (2005). A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. *Schizophrenia Research* 80 (1):45-53.

Honkola J, Hookana E, Malinen S, Kaikkonen KS, Junttila MJ, Isohanni M, Kortelainen M-L, et al (2012). Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. *European Heart Journal* 33:745-751.

Jolly K, Gammage MD, Cheng, KK, Bradburn, P, Banting, MV, and Langman, MJS (2009). Sudden death in patients receiving drugs tending to prolong the QT interval. *British Journal of Clinical Pharmacology* 68 (5):743-751.

Osborn DPJ, Levy G, Nazareth I, Petersen I, Islam A, and King MB (2007). Relative risk of Cardiovascular and Cancer Mortality in People With Severe Mental Illness From the United Kingdom's General Practice Research Database. *Archives of General Psychiatry* 64:242-249.

Pariante A, Fourrier-Reglat A, Ducruet T, Farrington P, Beland SG, Dartigues JF, Moore N, et al (2012). Antipsychotic use and myocardial infarction in older patients with treated dementia. *Archives of Internal Medicine* 172 (8):654-655.

Ray WA, Chung CP, Murray KT, Hall K, and Stein CM (2009). Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. *NEJM* 360 (3):225-235.

Straus SMJM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma H, Sturkenboom MCJM, et al (2004). Antipsychotics and the Risk of Sudden Cardiac Death. *Archives of Internal Medicine* 164:1293-1297.

Antidepressants and Heart Disease

Almeida OP, Alfonso H, Hankey GJ, and Flicker L (2010). Depression, antidepressant use and mortality in later life: the Health in Men Study. *PLoS One* 5(6):e11266.

Blanchette CM, Simoni-Wastila L, Zuckerman IH, and Stuart B (2008). A Secondary Analysis of a Duration Response Association Between Selective Serotonin Reuptake Inhibitor use and the Risk of Acute Myocardial Infarction in the Aging Population. *Annals of Epidemiology* 18: 316-321.

Jolly K, Gammage MD, Cheng KK, Bradburn P, Banting MV, and Langman MJS (2009). Sudden death in patients receiving drugs tending to prolong the QT interval. *British Journal of Clinical Pharmacology* 68 (5):743-751.

Tata LJ, West J, Smith C, Farrington P, Card T, Smeeth L, and Hubbard, R (2005). General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. *Heart* 91:465-471.

Wang W, Kubzansky LD, Kawachi I, Rexrode KM, Kroenke CH, Glynn RJ, Garan H, et al (2009). Depression and Risk of Sudden Cardiac Death and Coronary Heart Disease in Women: Results from the Nurses' Health Study. *Journal of the American College of Cardiology* 53(11):950-958.

Antipsychotics and Stroke

Douglas IJ and Smeeth L (2008). Exposure to antipsychotics and risk of stroke: self controlled case series study. *BMJ* 337:a1227.

Jerrell JM and McIntyre RS (2007). Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. *Human Psychopharmacology* 22 (6):361-364.

Lin HC, Hsiao FH, Pfeiffer S, Hwang YT, and Lee HC (2008). An increased risk of stroke among young schizophrenic patients. *Schizophrenia Research* 101 (1-3): 234-241.

Osborn DPJ, Levy G, Nazareth I, Petersen I, Islam A, and King MB (2007). Relative risk of Cardiovascular and Cancer Mortality in People With Severe Mental Illness From the United Kingdom's General Practice Research Database. *Archives of General Psychiatry* 64:242-249.

Percudani M, Barbui C, Fortino I, Tansella M, and Petrovich, L (2005). Second-Generation Antipsychotics and Risk of Cerebrovascular Accidents in the Elderly. *Journal of Clinical Psychopharmacology* 25 (5):468-470.

Sacchetti E, Trifiro G, Caputi A, Turrina C, Spina E, Cricelli C, Brignoli O, et al (2008). Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. *Journal of Psychopharmacology* 22(1): 39-46.

Wang S, Linkletter C, Dore D, Mor V, Buka S, and Maclure M (2012). Age, antipsychotics, and the risk of ischemic stroke in the Veterans Health Administration. *Stroke* 43 (1):28-31.

Antidepressants and Stroke

Coupland, C, Dhiman P, Morriss, R, Arthur, A, Barton, G, and Hippisley-cox, J (2011). Antidepressant use and risk of adverse outcomes in older people: population based cohort study. *BMJ* 343:d4551.

Hackam, DG and Mrkobrada, M (2012). Selective serotonin reuptake inhibitors and brain hemorrhage. *Neurology* 79:1862-1865.

Krantz, DS, Whittaker KS, Francis JL, Rutledge T, Johnson BD, Barrow G, McClure, C, et al (2009). Psychotropic Medication use and Risk of Adverse Cardiovascular Events in Women with Suspected Coronary Artery Disease: Outcomes from the Women's Ischemia Syndrome Evaluation (WISE) Study. *Heart* 95(23): 1901-1906.

Pan A, Okerke OI, Sun Q, Logroscino G, Manson JE, Willett WC, Ascherio A, et al (2011). Depression and incident stroke in women. *Stroke* 42 (10):2770-2775.

Smoller, JW, Allison, A, Cochrane, BB, Curb, JD, Perlis, RH, Robinson JG, Rosal, MC, et al (2009). Antidepressant Use and Risk of Incident Cardiovascular Morbidity and Mortality Among Postmenopausal Women in the Women's Health Initiative Study. *Archives of Internal Medicine* 169 (22):2128-2139.

Trifiro, G, Dieleman, J, Sen, EF, Gambassi, G, and Sturkenboom MCJM (2010). Risk of Ischemic Stroke Associated With Antidepressant Drug Use in Elderly Persons. *Journal of Clinical Psychopharmacology* 30(3):252-258.

Wu, C-S, Wang, S-C, Cheng, Y-C, and Gau, SS (2011). Association of Cerebrovascular Events with Antidepressant Use: A Case-Crossover Study. *American Journal of Psychiatry* 168 (5):511-521.

Antiepileptic Drugs and Stroke

Chuang Y-C, Chuang H-Y, Lin T-K, Chang C-C, Lu C-H, Chang W-N, Chen S-D, et al (2012). Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. *Epilepsia* 53 (1):120-128.

Cockerell OC, Johnson AL, Sander JW, Hart YM, Goodridge DM, and Shorvon SD (1994). Mortality from epilepsy: results from a prospective population-based study. *Lancet* 344 (8927):918-921.

Gruppo R, Degrauw A, Fogelson H, Glauser T, Balasa V, and Gartside P (2000). Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. *Journal of Pediatrics* 137 (5):714-718.

Lo-Pinto C and Mintzer S (2010). Antiepileptic Drugs and Markers of Vascular Risk. *Current Treatment Options in Neurology* 12 (4):300-308.

Olesen JB, Abildstrom SZ, Erdal J, Gislason GH, Weeke P, Andersson C, Torp-Pedersen C, et al (2011). Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study. *Pharmacoepidemiology and Drug Safety* 20:964-971.

Antipsychotic Drugs and Diabetes

Carlson C, Hornbuckle K, DeLisle F, Kryzhanovskaya L, Breier A, and Cavazzoni P (2006). Diabetes mellitus and antipsychotic treatment in the United Kingdom. *European Neuropsychopharmacology* 16 (5):366-375.

De Hert M, Detraux J, van Winkel R, Yu W, and Correll CU (2011). Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. *National Review of Endocrinology* 8 (2):114-126.

Duncan E, Dunlop BW, Boshoven W, Woolson SL, Hamer RM, and Phillips LS (2007). Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration protocol. *International Clinical Psychopharmacology* 22 (1):1-11.

Henderson DC, Cagliero E, Copeland PM, Louie PM, Borba CP, Fan X, Freudenreich O, et al (2007). Elevated hemoglobin A1C as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. *Journal of Clinical Psychiatry* 68 (4):533-541.

Jerrell JM, McIntyre RS, and Tripathi A (2010). Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. *Clinical Schizophrenia and Related Psychoses* 4 (3):161-168.

Kessing LV, Thomsen AF, Mogensen UB, and Andersen PK (2010). Treatment with antipsychotics and the risk of diabetes in clinical practice. *British Journal of Psychiatry* 197:266-271.

Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, et al (2010). Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs. *Archives of General Psychiatry* 67 (1):17-24.

Nielsen J, Skadhede S, and Correll CU (2010). Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients. *Neuropsychopharmacology* 35:1997-2004.

Saddicha S, Manjunatha N, Ameen S, and Akhtar S (2008). Diabetes and schizophrenia – effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. *Acta Psychiatrica Scandinavica* 117 (5):342-347.

Antidepressant Drugs and Diabetes

Andersohn F, schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. *American Journal of Psychiatry* 166 (5):591-598.

Jerrell JM (2010). Neuroendocrine-related adverse events associated with antidepressant treatment in children and adolescents. *CNS Neuroscience and Therapeutics* 16 (2):83-90.

Khoza S, Barner JC, Bohman TM, Rascati K, Lawson K, and Wilson JP (2012). Use of antidepressant agents and the risk of type 2 diabetes. *European Journal of Clinical Pharmacology* 68 (9):1295-1302.

Kivimaki M, Hamer M, Batty GD, Geddes JR, Tabak AG, Pentti J, Virtanen M, et al (2010). Antidepressant Medication Use, Weight Gain, and Risk of Type 2 Diabetes. *Diabetes Care* 33 (12):2611-2616.

Pan A, Sun Q, Okereke OI, Rexrode KM, Rubin RR, Lucas M, Willett WC, et al (2012). Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. *Diabetologia* 55 (1):63-72.

Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, Willett WC, et al (2010). Bidirectional association between depression and type 2 diabetes mellitus. *Archives of Internal Medicine* 170 (21):1884-1891.

Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, Haffner SM, et al (2008). Elevated Depression Symptoms, Antidepressant Medicine Use, and Risk of Developing Diabetes During the Diabetes Prevention Program. *Diabetes Care* 31 (3):420-426.

Antiepileptic Drugs and Diabetes/Insulin Resistance

Luef G, Rauchenzauner M, Waldmann M, Sturm W, Sandhofer A, Seppi K, Trinkla E, et al (2009). Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. *Epilepsy Research* 86:42-47.

Mania M, Javashvili L, Kasradze S, and Okujava N (2011). Fasting insulin and HOMA-index changes in patients treated with valproic acid. *Georgian Medical News* 199:48-52.

Pylvanen V, Pakarinen A, Knip M, and Isojarvi J (2006). Characterization of insulin secretion in valproate-treated patients with epilepsy. *Epilepsia* 47 (9):1460-1464.

Saleh DA, Ismail MA, and Ibrahim AM (2012). Non alcoholic fatty liver disease, insulin resistance, dyslipidemia and atherogenic ratios in epileptic children and adolescents on long term antiepileptic drug therapy. *Pakistan Journal of Biological Science* 15 (2): 68-77.

Death Rates Among Patients Exposed to Psychiatric Drugs

Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, and Kessing LV (2006). Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: a pharmacoepidemiological study. *Journal of Neurology, Neurosurgery, and Psychiatry* 77 (6):781-783.

Brodersen A, Licht RW, Vestergaard P, Olesen AV, and Mortensen PB (2000). Sixteen-year mortality in patients with affective disorder commenced on lithium. *British Journal of Psychiatry* 176:429-433.

Kessing LV, Sondergard L, Forman JL, and Andersen PK (2009). Antidepressants and dementia. *Journal of Affective Disorder* 117 (1-2):24-29.

Kessing LV, Thomsen AF, Mogensen UB, and Andersen PK (2010). Treatment with antipsychotics and the risk of diabetes in clinical practice. *British Journal of Psychiatry* 197:266-271.

Modestin J, Wehrli MV, Stephan PL, and Agarwalla P (2008). Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. *Schizophrenia Research* 100:97-107.

Morgan MG, Scully PJ, Youssef HA, Kinsella A, Owens JM, and Waddington JL (2003). Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. *Psychiatry Research* 117:127-135.

Vestergaard P and Aagaard J (1991). Five-year mortality in lithium-treated manic-depressive patients. *Journal of Affective Disorder* 21 (1):33-38.

Waddington JL, Hanafy AY, and Kinsella A (1998). Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. *British Journal of Psychiatry* 173:325-329.

Dementia

5-8% of Americans over age 65 will develop dementia:

<http://www.depression-guide.com/dementia.htm>

http://www.health24.com/medical/Condition_centres/777-792-798-4838,64877.asp

Alliance for Aging Research (last updated 6/8/10). The Silver Book: Chronic Disease and Medical Innovation in an Aging Nation. Accessed on 7/4/10 at:

<http://www.silverbook.org/fact/1356#>

American Psychiatric Association, *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition – Text Revision* (Arlington, VA: American Psychiatric Association, 2000), 169.

References for Grace E. Jackson's lecture

Brain Repair

Delivered on 2 November 2012 at ISEPP conference – Philadelphia PA

Robbins, G.B. (2006). "Alzheimers and Dementia Update." Accessed on 5/31/09 at: www.atsu.edu/kcom/cme/previous_programs/ppt/Robbins-Alzheimers_Dementia_TOMA_2006.ppt

UNC Institute on Aging (October 2006). "U.S. Aging Demographics." Accessed on May 20, 2009 at: www.aging.unc.edu/infocenter/slides/usaging.ppt

Alzheimer's Disease

Clarke NA, Hartmann T, Jones EL, Ballard CG, and Francis PT (2011). Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid AB40 and tau in patients with intractable unipolar depression. *Internal Journal of Geriatric Psychiatry* 26 (12):1283-1291.

Frisoni GB, Prestia A, Geroldi C, Adorni A, Ghidoni R, Amicucci G, Bonetti M, et al (2011). Alzheimer's CSF markers in older schizophrenia patients. *International Journal of Geriatric Psychiatry* 26 (6):640-648.

Geddes JW, Tekirian TL, Soultanian NS, Ashford JW, David DG, and Markesbery WR (1997). Comparison of Neuropathologic Criteria for the Diagnosis of Alzheimer's Disease. *Neurobiology of Aging* 18 (54):S99-S105.

Prohovnik I, Dwork AJ, Kaufman MA, and Willson N (1993). Alzheimer-type neuropathology in elderly schizophrenia patients. *Schizophrenia Bulletin* 19 (4):805-816.

Purohit DP, Perl DP, Haroutunian V, Powchik P, Davidson M, and Davis KL (1998). Alzheimer Disease and Related Neurodegenerative Diseases in Elderly Patients With Schizophrenia. *Archives of General Psychiatry* 55:205-211.

Rapp MA, Schnaider-Beeri M, Purohit DP, Reichenberg A, McGurk SR, Haroutunian V, and Harvey PD (2010). Cortical Neuritic Plaques and Hippocampal Neurofibrillary Tangles are Related to Dementia Severity in Elderly Schizophrenia Patients. *Schizophrenia Research* 116 (1):90-96.

Wisniewski HM, Constantinidis J, Wegiel J, Bobinski M, and Tarnawski M (1994). Neurofibrillary pathology in brains of elderly schizophrenics treated with neuroleptics. *Alzheimer Disease and Associated Disorders* 8 (4):211-227.

Alzheimer's Disease and Type III Diabetes

de la Monte, S (2012). Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease. *Current Alzheimer Research* 9:35-66.

de la Monte S and Wands J (2008). Alzheimer's Disease is Type 3 Diabetes – Evidence Reviewed. *Journal of Diabetes Science and Technology* 2 (6):1101-1113.

Duarte AI, Moreira PI, and Oliveira CR (2012). Insulin in Central Nervous System: More than Just a Peripheral Hormone. *Journal of Aging Research* 2012:384017.

Frisardi V, Solfrizzi V, Capurso C, Imbimbo BP, Vendemiale G, Seripa D, Pilotto A, et al (2010). Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome? *Journal of Alzheimer's Disease* 21 (1):57-63.

Hallschmid M and Schultes B (2009). Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders? *Diabetologia* 52:2264-2269.

Mitochondrial Impairment, Oxidative Stress, and Parkinson's Disease

Armon C, Shin C, Miller P, Carwile S, Brown E, Edinger JD, and Paul RG (1996). Reversible parkinsonism and cognitive impairment with chronic valproate use. *Neurology* 47:626-635.

Asanuma M, Miyazaki I, and Ogawa N (2003). Dopamine or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. *Neurotoxicity Research* 5 (3):165-176.

Azmitia EC and Nixon R (2008). Dystrophic Serotonergic Axons in Neurodegenerative Diseases. *Brain Research* 1217:185-194.

Cadet JL, Krasnova IN, Jayanthi S, and Lyles J (2007). Neurotoxicity of Substituted Amphetamines: Molecular and Cellular Mechanisms. *Neurotoxicity Research* 11 (3,4):183-202.

Christine CW, Garwood ER, Schrock LE, Austin DE, and McCulloch CE (2010). Parkinsonism in patients with a history of amphetamine exposure. *Movement Disorders* 25 (2):228-231.

Daubert EA, Heffron DS, Mandell JW, and Condron BG (2010). Serotonergic dystrophy induced by excess serotonin. *Molecular and Cellular Neuroscience*. 44 (3):297-306.

Dauer W and Przedborski S (2003). Parkinson's Disease: Mechanisms and Models. *Neuron* 39:889-909.

Finsterer J (2012). Cognitive dysfunction in mitochondrial disorders. *Acta Neurologica Scandinavica* 126:1-11.

Gandhi S and Abramov AY (2012). Mechanism of Oxidative Stress in Neurodegeneration. *Oxidative Medicine and Cellular Longevity* 2012: Article 428010.

Globus MYT, Weter P, Busto R, and Dietrich WD (1992). Ischemia-Induced Extracellular Release of Serotonin Plays a Role in CA1 Neuronal Cell Death in Rats. *Stroke* 23:1595-1601.

Hastings TG (2009). The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease. *The Journal of Bioenergetics and Biomembranes* 41:469-472.

Jellinger K. "Neuropathologic Findings after Neuroleptic Long-Term Therapy," in L. Roizin, H. Shiraki, and N. Grcevic, Ed. *Neurotoxicology* (New York: Raven Press, 1977), 25-42.

Jiang XR, Wrona MZ, and Dryhurst G (1999). Tryptamine-4,5-dione, a putative endotoxic metabolite of the superoxide-mediated oxidation of serotonin, is a mitochondrial toxin: possible implications in neurodegenerative disorders. *Chemical Research and Toxicology* 12 (5):429-436.

Kotogal V, Bohnen NI, Muller ML, Koeppe RA, Frey KA, and Albin RL (2012). Cerebral Amyloid Deposition and Serotonergic Innervation in Parkinson Disease. *Archives of Neurology* [epub ahead of print: Sept 10].

Kuhn DM and Arthur Jr R (1998). Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons. *Journal of Neuroscience* 18 (18):7111-7117.

Kumar H, Lim HW, More SV, Kim BW, Koppula S, Kim IS, and Choi DK (2012). The Role of Free Radicals in the Aging Brain and Parkinson's Disease: Convergence and Parallelism. *International Journal of Molecular Sciences* 13:10478-10504.

Munoz P, Huenchuguala S, Paris I, and Segura-Aguilar J (2012). *Parkinson's Disease* 2012: Article 920953.

Navailles S, Carta M, Guthrie M, and De Deurwaerdere P (2011). L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease. *Central nervous system agents in medicinal chemistry* 11 (4):305-320.

Nayyar T, Bubser M, Ferguson MC, Neely MD, Goodwin JS, Montine TJ, Deutch AY, et al (2009). Cortical serotonin and norepinephrine denervation in parkinsonism: Preferential loss of the beaded serotonin innervation. *European Journal of Neuroscience* 30 (2):207-216.

Neustadt J and Pieczenik (2008). Medication-induced mitochondrial damage and disease. *Molecular Nutrition and Food Research* 52:780-788.

Politis M and Loane C (2011). Serotonergic dysfunction in Parkinson's disease and its relevance to disability. *Scientific World Journal* 11:1726-1734.

Sadasivan S, Pond BB, Pani AK, Qu C, Jiao Y, and Smeyne RJ (2012). Methylphenidate Exposure Induced Dopamine Neuron Loss and Activation of Microglia in the Basal Ganglia of Mice. *PLoS ONE* 7 (3):e33693.

Wranga MZ and Dryhurst G (1998). Oxidation of serotonin by superoxide radical: implications to neurodegenerative brain disorders. *Chemical Research and Toxicology* 11 (6):639-650.

Other Forms of Drug-Induced Dementia

Adityanjee, Munshi KR, and Thampy A (2005). The syndrome of irreversible lithium-effectuated neurotoxicity. *Clinical Neuropharmacology* 28 (1):38-49.

Babinsky E and Levene RS (2012). Multisystem Atrophy Made Worse by Lithium Treatment in a Hospice Patient: A Case Report. *American Journal of Hospice and Palliative Medicine* 29 (7):570-573.

Casanova B, de Entrambasaugas M, Perla C, Gomez-Siurana E, Beneto A, and Burguera JA (1996). Lithium-induced Creutzfeldt-Jakob syndrome. *Clinical Neuropharmacology* 19 (4):356-359.

Dethy S, Manto M, Bastianelli E, Gangji V, Laute MA, Goldman S, and Hildebrand J (1997). Cerebellar spongiform degeneration induced by acute lithium intoxication in the rat. *Neuroscience Letters* 224 (1):25-28.

Evans MD, Shinar R, and Yaari R (2011). Reversible dementia and gait disturbance after prolonged use of valproic acid. *Seizure* 20 (6):509-511.

Finelli PF (1992). Drug-Induced Creutzfeldt-Jakob Like Syndrome. *Journal of Psychiatry and Neuroscience* 17 (3):103-105.

Fischera M, Anneken K, Evers S, Kloska S, and Husstedt IW (2009). Cerebellar atrophy after long-term treatment with low-dose lithium. *Pharmacopsychiatry* 42 (3):125-126.

Hexom B and Barthel RP (2004). Lithium and Pseudotumor Cerebri. *Journal of the American Academy of Child and Adolescent Psychiatry* 43 (3):247.

Kharkar S, Hernandez R, Batra S, Metellus P, Hillis A, Williams MA, and Rigamonti D (2011). Cognitive impairment in patients with Pseudotumor Cerebri Syndrome. *Behavioral Neurology* 24 (2):143-148.

Levine SH and Puchalski C (1990). Pseudotumor cerebri associated with lithium therapy in two patients. *Journal of Clinical Psychiatry* 51 (6):251-253.

Papazian O, Canizales E, Alofonso I, Archila R, Duchowny M, and Aircardi J (1995). Reversible Dementia and Apparent Brain Atrophy During Valproate Therapy. *Annals of Neurology* 38:687-691.

Pavlovic A, Marley J, and Sivakumar V (2011). Development of frontotemporal dementia in a case of bipolar affective disorder: is there a link? *BMJ Case Reports* 0920103033.

Saul RF, Hamburger HA, and Selhorst JB (1985). Pseudotumor cerebri secondary to lithium carbonate. *JAMA* 253:2869-2870.

Smith SJM and Kocen RS (1988). A Creutzfeldt-Jakob like syndrome due to lithium toxicity. *Journal of Neurology, Neurosurgery, and Psychiatry* 51:120-123.

Thirugnanasampanthan U, Foster A, and Rauch RA (2006). Reversible cerebral atrophy: a case report and literature review. *General Hospital Psychiatry* 28 (5): 458-462.

Brain Repair

Nutrition

Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, and Schlaefke S (2012). Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. *Journal of Psychiatric Research* 46 (6):716-723.

Kaschel R (2011). Specific memory effects of Ginkgo biloba extract EGb 761 in middle-aged healthy volunteers. *Phytomedicine* 18 (14):1202-1207.

Krikorian R, Eliassen JC, Boespflug EL, Nash TA, and Sidler MD (2010). Improved cognitive-cerebral function in older adults with chromium supplementation. *Nutritional Neuroscience* 13 (3):116-122.

Lautenschlager NT, Ihl R, and Muller WE (2012). Ginkgo biloba extract EGb 761 In the context of current developments in the diagnosis and treatment of age-related cognitive decline and Alzheimer's disease: a research prospective. *International Psychogeriatrics* 24 Suppl 1:S46-S50.

Mazza M, Capuano A, Bria P, and Mazza S (2006). Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. *European Journal of Neurology* 13 (9):981-985.

Mishra S and Palanivelu K (2008). The effect of curcumin (turmeric) on Alzheimer's disease: An overview. *Annals of Indian Academy of Neurology* 11 (1):13-19.

Napryeyenko O, Sonnik G, and Tartakovsky I (2009). Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomized controlled trial. *Journal of Neurological Science* 283 (1-2):224-229.

Ng TP, Chiam PC, Lee T, Chua HC, Lim L, and Kua EH (2006). Curry Consumption and Cognitive Function in the Elderly. *American Journal of Epidemiology* 164 (9):898-906.

Weinmann S, Roll S, Schwarzbach C, Vauth C, and Willich SN (2010). Effects of Ginkgo biloba in dementia: a systematic review and meta-analysis. *BMC Geriatrics* 10:14.

Antioxidants

Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC, and Golde DW (1997). Vitamin C Crosses the Blood-Brain Barrier in the Oxidized Form Through the Glucose Transporters. *Journal of Clinical Investigation* 100 (11):2842-2848.

de la Monte, S (2012). Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease. *Current Alzheimer Research* 9:35-66.

Joseph J, Cole G, Head E, Ingram D (2009). Nutrition, brain aging, and neurodegeneration. *Journal of Neuroscience* 29 (41):12795-12801.

Krikorian R, Shidler MD, Nash TA, Kalt W, Vinqvist-Tymchuk MR, S hukitt-Hale B, and Joseph JA (2010). Blueberry supplementation improves memory in older adults. *Journal of Agriculture and Food Chemistry* 58 (7):3996-4000.

Vauzour D (2012). Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects. *Oxidative Medicine and Cellular Longevity* 2012:914273.

Vasanthi HR, Parameswari RP, DeLeiris J, and Das DK (2012). Health benefits of wine and alcohol from neuroprotection to heart health. *Frontiers in Bioscience (elite edition)* 4:1505-1512.

Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N Jr et al (2010). Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. *Alzheimer's Dementia* 6 (6):456-464.

Vitamin Depletion

Klopouth BS (3/2011). Interactions in Clinical Practice: Drug-Supplement, Drug-Nutrient, Drug-Herb. Accessed on 2/28/12 at:

http://www.eatwellmd.org/docs/Annual%20Meeting%202011/Presentations/Yuliya%20Klopouh_Presentation.pdf

Prescription Drug Depletion Chart. Accessed on 2/28/12 at:

<http://www.docstoc.com/docs/7967360/Prescription-Drug-Depletion-Chart>

Simon A. Drug-Induced Nutrient Depletions. Accessed on 2/28/12 at:

<http://integrativrxpharmacy.com/drug-induced%20nutrient040709b.pdf>

Wagner DT. Common Drugs Deplete Nutrients. Accessed on 2/28/12 at:

<http://www.ntrifarmacy.com/articles/alive2.html>

Caffeine

Arendash GW and Cao C (2010). Caffeine and coffee as therapeutics against Alzheimer's disease. *Journal of Alzheimer's Disease* 20 Suppl 1:S117-S126.

Chen X, Gribi O, and Geiger JD (2010). Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. *Journal of Alzheimer's Disease* 20 Suppl 1:S127-S141.

Eskelinen MH and Kivipelto M (2010). Caffeine as a protective factor in dementia and Alzheimer's disease. *Journal of Alzheimer's Disease* 20 Suppl 1:S167-S174.

Han ME, Kim HJ, Lee YS, Kim DH, Choi JT, Pan CS, Yoon S, et al (2009). Regulation of cerebrospinal fluid production by caffeine consumption. *BMC Neuroscience* 10:110.

Wostyn P, Van Dam D, Audenaert K, and De Deyn PP (2011). Increased Cerebrospinal Fluid Production as a Possible Mechanism Underlying Caffeine's Protective Effect against Alzheimer's Disease. *International Journal of Alzheimer's Disease* 2011:617420.

Exercise

Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA (2012). Total daily physical activity and the risk of AD and cognitive decline in older adults. *Neurology* 78 (17);1323-1329.

Mortimer JA, Ding D, Borenstein AR, DeCarli C, Guo Q, Wu Y, Zhao Q, Chu S (2012). Changes in brain volume and cognition in a randomized trial of exercise and social interaction in a community-based sample of non-demented Chinese elders. *Journal of Alzheimer's Disease* 30 (4):757-766.

Scarmeas N, Luchsinger JA, Brickman AM, Cosentino S, Schupf N, Xin-Tang M, Gu Y, and Stern Y (2011). Physical activity and Alzheimer disease course. *American Journal of Geriatric Psychiatry* 19 (5):471-481.

Venturelli M, Scarsini R, And Schene F (2011). Six-month walking program changes cognitive and ADL performance in patients with Alzheimer. *American Journal of Alzheimer's Disease and Other Dementias* 26 (5):381-388.

Winchester J, Dick MB, Gillen D, Reed B, Miller B, Tinklenberg J, Mungas D, et al (2012). Walking stabilizes cognitive functioning in Alzheimer's disease (AD) across one year. *Archives of Gerontology and Geriatrics* [epub ahead of print].

Nature

Detweiler MB, Sharma T, Detweiler JG, Murphy PF, Lane S, Carman J, Chudhary AS, et al (2012). What is the evidence to support the use of therapeutic gardens for the elderly? *Psychiatry Investigation* 9 (2):100-110.

Irvine KN and Warber SL (2002). Greening healthcare: practicing as if the natural environment really mattered. *Alternative Therapies in Health and Medicine* 8 (5):76-83.

Jarrott SE and Gigliotti CM (2010). Comparing responses to horticultural-based and traditional activities in dementia care programs. *American Journal of Alzheimer's Disease and Other Dementias* 25 (8):657-665.

Li Q (2010). Effect of forest bathing trips on human immune function. *Environmental Health and Preventive Medicine* 15:9-17.

Park BJ, Tsunetsugu Y, Kasetani T, Hirano H, Kagawa T, Sato M, and Miyazaki Y (2007). Physiological effects of Shinrin-yoku (taking the atmosphere of the forest) – using salivary cortisol and cerebral activity as indicators. *Journal of Physiological Anthropology* 26 (2):123-128.

Simons LA, Simons J, McCallum J, Friedlander Y (2006). Lifestyle factors and risk of dementia: Dubbo Study of the elderly. *Medical Journal of Australia* 184 (2):68-70.

Cognitive enrichment

Cheng ST, Chow PK, song YQ, Yu EC, Chan AC, Lee TM, and Lam JH (2012). Mental and Physical Activities Delay Cognitive Decline in Older Persons With Dementia. *American Journal of Geriatric Psychiatry* (Nov 5 - epub ahead of print).

Holmes C, Knights A, Dean C, Hodkinson S, and Hopkins V (2006). Keep music live: music and the alleviation of apathy in dementia subjects. *International Psychogeriatrics* 18 (4):623-630.

Knapp M, Thorgrimsen L, Patel A, Spector A, Hallam A, Woods B, and Orrell M (2006). Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis. *British Journal of Psychiatry* 188:574-580.

Orrell M, Yates LA, Burns A, Russell I, Woods RT, Hoare Z, Moniz-Cook E, et al (2012). Individual Cognitive Stimulation Therapy for dementia (iCST): study protocol for a randomized controlled trial. *Trials* 13:172.

Social engagement

Krueger SR, Wilson RS, Kamenetsky JM, Barnes LL, Bienias JL, and Bennett DA (2009). Social Engagement and Cognitive Function in Old Age. *Experimental Aging Research* 35 (1):45-60.

Wang HX, Karp A, Winblad B, and Fratiglioni L (2002). Late-Life Engagement in Social and Leisure Activities is Associated with a Decreased Risk of Dementia: A Longitudinal Study from the Kungsholmen Project. *American Journal of Epidemiology* 155 (12):1081-1087.